Initial positive data from Phase 2 of BEXMAB
Faron Pharmaceuticals Ltd. (“Faron” or the “Company”) Inside Information: Faron Reports Initial Positive Phase 2 Read-out in HMA-resistant MDS Company announcement, Inside Information, 20 May 2024 at 7:00 a.m. BST / 9:00 a.m. EEST Key highlights - Initial preliminary phase 2 read-out from the BEXMAB Trial confirms earlier positive Phase 1 findings in MDS patients with prior HMA failure - In Phases 1 & 2, 14 MDS patients who are refractory or relapsed on HMA (r/r MDS) and have no effective treatment options, show an objective